Table of Contents Author Guidelines Submit a Manuscript
International Journal of Breast Cancer
Volume 2011 (2011), Article ID 523276, 8 pages
http://dx.doi.org/10.4061/2011/523276
Research Article

Obesity Is an Independent Predictor of Poor Survival in Metastatic Breast Cancer: Retrospective Analysis of a Patient Cohort Whose Treatment Included High-Dose Chemotherapy and Autologous Stem Cell Support

1Division of Hematology/Oncology, Department of Medicine, UCSD, CA 92093, USA
2Moores Cancer Center, 3855 Health Sciences Drive, La Jolla, Ca 92093-0829, USA
3Division of Biostatistics and Bioinformatics, Department of Family and Preventive Medicine, UCSD, CA 92093, USA
4Division of Bone and Marrow Transplantation, Department of Medicine, UCSD, CA 92093, USA

Received 4 April 2011; Accepted 5 May 2011

Academic Editor: Filippo Montemurro

Copyright © 2011 A. von Drygalski et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

The purpose of the study was to identify predictors of long-term survival in metastatic breast cancer (MBC). A cohort of 96 patients, who received high-dose chemotherapy with autologous stem cell support (HD-ASCT) as part of their treatment, was analyzed. Percent long-term survival at 10 years was 24.5% (CI 17.2–34.9%) when metastasis was diagnosed and 14.4% (CI 8.7–23.9%) when MBC was diagnosed. Survival was impacted significantly by body mass index (BMI). Median overall survival from initial diagnosis or from time of metastasis for patients with BMIs ≤30 and >30 (obese) was 7.1 (CI 4.4–8.7) and 3.2 years (2.41–6.75), respectively, or 3.2 or 2.3 years (all 𝑃 = 0 . 0 2 ). Also, obesity was the only independent patient-related predictor of time to metastasis and of survival. While obesity is linked with poor outcomes in earlier stages of breast cancer, this has not been previously reported for MBC.